Abstract. There is a need for new options for reducing the side effects of cancer treatment, without compromising efficacy, enabling patients to complete treatment regimens. The botanical compound LCS101 exhibits inhibitory effects on cancer cell growth, and reduces chemotherapy-induced hematological toxicities. The aim of the present study is to examine the selectivity of the effects of the compound, alone and in conjunction with conventional chemotherapy agents, on cancer cell proliferation. The effects of LCS101 were tested on a number of cancer cell lines (breast, MCF7, MDA-MB-231; colorectal, HCT116; prostate, PC-3, DU-145) and on non-tumorigenic normal human epithelial cells (breast, MCF10A; prostate, EP#2). Cell viability was analyzed using an XTT assay and observed by light microscopy. Necrosis and apoptosis were examined using FACS analysis and immunoblotting. LCS101 selectively induced cell death in breast, colon and prostate cancer cell lines, as measured by XTT assay. Light microscopy and FACS analysis showed changes indicative of a necrotic process. LCS101 was also found to induce PARP-1 reduction in breast cancer cells, with no effect on non-tumorigenic breast epithelial cells. While LCS101 increased cell death in cancer cells exposed to doxorubicin and 5-FU, it showed a protective effect on non-tumorigenic human epithelial cells from chemotherapy-induced cell death. A similar selective effect was observed with apoptosis-associated PARP-1 cleavage. The findings demonstrate that the anti-proliferative effects exhibited by the botanical compound LCS101 are selective to cancer cells, and offer protection to non-tumorigenic normal epithelial cells from chemotherapy agents.

Introduction

Cancer is a leading cause of death worldwide (1). Current conventional anticancer treatments incorporate the use of chemotherapy, targeted therapies and radiation treatment. The utilization of these treatments is often limited by severe adverse effects, which often lead to dose reductions and treatment delays. It is therefore important to search for therapies which can reduce the side effects of anticancer treatments without altering their efficacy or increasing toxicity. Such therapies would not only improve the quality of life of patients with cancer but would also help patients complete their anticancer regimen (2).

LCS101 is a botanical compound developed for the treatment of patients with solid cancers, based on the principles of traditional Chinese medicine (TCM). The formula contains concentrated extracts from the following herbs: Astragalus membranaceus, Atractylodes macrocephala, Citrus reticulate, Glehnia littoralis, Ligustrum lucidum, Lycium chinense, Millettia reticulata, Oldenlandia diffusa, Ophiopogon japonicus, Paeonia lactiflora, Paeonia obovata, Poria cocos, Prunella vulgaris and Scutellaria barbata. Extracts of these compound are manufactured in accordance with good manufacturing practice (GMP) conditions, and are imported under license (Zen Herbs Inc., Rehovot, Israel), in accordance with the regulations of the Israel Ministry of Health. All batches of the compound are analyzed and certified to be free of heavy metals, microbial contamination, pesticide residues and mycotoxins. The herbal components of LCS101 are considered to be safe for human consumption, and have not been found to alter the bioavailability or efficacy of anticancer drugs (3).

In earlier preclinical research, LCS101 was shown in vitro to inhibit breast cancer cell survival in a dose-dependent manner on human breast carcinoma cell lines MDA-231, MDA-453 and T47D. The compound has also shown dose-dependent inhibition of cell growth (T47D cell line), as well as

Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment

ZOYA COHEN1*, YAIR MAIMON1*, MERAV YOELI-LERNER1, PEIYING YANG2, NOAH SAMUELS1 and RAANAN BERGER3

1Tal Center for Integrative Medicine, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; 2Department of General Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; 3Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel

Received August 10, 2014; Accepted September 25, 2014

DOI: 10.3892/ijo.2014.2711

Correspondence to: Dr Yair Maimon, Tal Center for Integrative Medicine, Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
E-mail: yair@tcm.org.il

*Contributed equally

Key words: cancer, chemotherapy, botanical compounds, cytotoxicity, necrosis, PARP-1, protective
a dose-dependent increase in cell apoptosis, as demonstrated by sub-diploid DNA content (4). In vivo studies have shown that LCS101 increases peripheral neutrophil counts in doxorubicin-treated mice with breast cancer, preserving splenic erythrocyte and leucocyte counts (unpublished data). LCS101 has also been shown to have indirect anticancer effects, with immunomodulating effects which include the promotion of T-cell proliferation, NK cell activation and cytokine (TNFα) activity, as well as the correction of reduced IFN-γ following exposure to doxorubicin (5). In clinical studies, LCS101 was shown to reduce anemia and neutropenia in female patients with locally advanced breast cancer undergoing anthracycline and taxane-based treatments. In clinical practice and research LCS101 was found to be both safe and well-tolerated by patients (6).

The purpose of the present study was to examine the selectivity of the anticancer effects of LCS101 on cancer cells, and to investigate its impact on the anticancer activity of the chemotherapeutic agents doxorubicin and 5-fluorouracil.

Materials and methods

Antibodies and reagents. Primary antibodies: rabbit anti-human PARP-1 (polyclonal, 1:1,000) and rabbit anti-human caspase-3 (monoclonal, 1:1,000) were from Cell Signaling human PARP-1 (polyclonal, 1:1,000) and rabbit anti-human GAPDH (monoclonal, 1:1,000) and mouse anti-human GAPDH (monoclonal, 1:100,000) were from Santa Cruz Biotechnology (Dallas, TX, USA). Secondary antibodies: peroxidase-conjugated goat anti-rabbit, goat anti-mouse and rabbit anti-goat IgG (H+L) antibodies were from Jackson (Baltimore Pike West Grove, PA, USA). Propidium iodide, MG132 (Z-Leu-Leu-Leu-al), insulin, doxorubicin, 5-fluorouracil, cholera toxin and hydrocortisone were from Sigma-Aldrich. DMEM F/12, high glucose DMEM, L-glutamine, donor horse serum, fetal bovine serum, recombinant human EGF, trypsin and PBS were from Biological Industries (Beit-Ha-Emek, Israel). Prostate epithelial growth medium was from Lonza (Walkersville, MD, USA).

Cell culture. Human MCF10A non-tumorigenic breast epithelial cells were propagated in DMEM F/12 medium supplemented with 5% horse serum, 2 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 50 ng/ml hydrocortisone and 10 µg/ml insulin. Human HCT116 colorectal carcinoma, PC-3 prostate adenocarcinoma, DU-145 prostate carcinoma, MCF7 breast adenocarcinoma and MDA-MB-231 breast adenocarcinoma cells were propagated in high glucose DMEM supplemented with 10% fetal bovine serum and 2 mM L-glutamine. All cell lines were from American Type Tissue Collection (ATCC, USA) and were authenticated using STR analysis. Human EP#2 non-tumorigenic normal prostate epithelial cells were donated by Dr Orit Leshem (7) and propagated in prostate epithelial growth medium. All cells were propagated in a 37°C humidified incubator with 5% CO2.

Study compound. A dry extract powder of the formula (Zen Herbs Inc.) was dissolved in PBS at a concentration of 100 mg/ml. The solution was then centrifuged at 4300 g for 5 min, with the supernatant filtered through a 0.45-µM Millex PVDF filter (Merck Millipore, Tullagreen, Ireland). Solubility was estimated by cryophilization and weighting of the pellet, and was estimated to be ~50%. For convenience, the final stock concentration was designated at 100 mg/ml (w/v concentration of crude powder in PBS), enabling the comparison of the individual herbal components with their variable solubilities with the formula in its entirety.

**XTT viability assay.** Breast, prostate and colorectal cells were plated in triplicate into 96-well plates (MCF10A at 6x10⁵/w; MCF7, DU-145 and HCT116 at 3x10⁵/w; PC-3 and MDA-MB-231 at 4x10⁵/w; EP#2 - 8x10⁵/w), and allowed to attach and grow overnight. The medium was replaced with a fresh treatment-containing medium, and the cells were propagated for an additional 72 h. Cell viability was determined by XTT cell proliferation kit (Biological Industries) by replacing the medium with the fresh medium (in order to prevent interference of treatment color with XTT signal), and the addition of an XTT for 2-3 h. The resulting signal was measured by Power Wave X 340-I ELISA reader (Biotek Instruments, Winooski, VT, USA), with each cell line tested in at least three independent assays.

**FACS analysis.** Both cancer and non-tumorigenic cells were plated at a density of 0.6-1x10⁶/10 cm plate, and then treated the following day. The cells were collected by trypsinization into their own medium to prevent loss of dead cells, with each sample divided into two aliquots. The first aliquot was analyzed for necrosis following exposure to a free propidium iodide (PI) influx for 15 min. The second aliquot was fixed with 70% ice-cold ethanol, stained with PI and used for cell cycle and apoptosis analysis. Cell sorting was performed on a BD FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA). Cells were resolved on an FL-2 logarithmic scale for necrosis analysis and on an FL-2 linear scale for apoptosis (cell cycle) analysis, and later analyzed using a WinMDI 2.9 program (Purdue University Cytometry Laboratories, West Lafayette, IN, USA).

**Immunoblotting.** Cancer and non-tumorigenic cells were plated at a density of 6x10⁴/10 cm plate. On the following day cells were exposed to LCS101 treatments as indicated in the legends. After 24-72 h, the cells were collected by scraping, washed with cold PBS and lysed with RIPA (150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 0.5 M Tris pH 8.0), supplemented with complete mini protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). Protein concentration was determined with Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Samples (50 µg) were resolved by 8% SDS-PAGE, transferred to Protran BA-83 0.2 µm nitrocellulose membrane (Whatman, Piscataway, NJ, USA), blocked with 5% skimmed milk and immunoblotted with appropriate antibodies. The membrane was then washed thrice with TBST, incubated with corresponding HRP-conjugated secondary antibodies, probed with EZ-ECL enhanced chemiluminescence detection kit (Biological Industries) according to the manufacturer’s instructions and then exposed to Fuji Super RX film (Fujifilm, Tokyo, Japan).
RT-qPCR. Breast cancer cells were plated at a density of 6x10^5/10-cm plates and treated the following day with 3 mg/ml LCS101. After 24 h the cells were collected by scraping and washed with cold PBS. Total RNA was isolated using an RNeasy Mini kit (Qiagen, GmbH, Hilden, Germany). RNA concentration and quality were determined by optic density measurement (260, and 280 nm). The quality of the samples was further verified by electrophoresis on 1% agarose gel, stained with ethidium bromide to visualize the 18S and 28S rRNA bands. Complementary DNA (cDNA) was prepared using random primers and a High Capacity cDNA Reverse Transcription kit (AB Applied Biosystems, Foster City, CA, USA). cDNA was subjected to RT-qPCR on a StepOnePlus Real-Time PCR System using a Power SYBR Green PCR Master Mix (AB Applied Biosystems). The RT-qPCR was performed according to the manufacturer's instructions using the following primer sets: PARP-1 forward, 5'-AAGCTCTATCGAGTCGAGTACG-3'; reverse, 5-GAAGCTCAGAGACCCCATCC-3. GADPH forward, 5-TGGACCTCATGGCCCACA-3; reverse, 5-TCAGGGGTCTACATGGCAA-3. The expression levels of PARP-1 from triplicate reactions was determined by normalization to GAPDH according to the manufacturer's instructions.

Results

LCS101 selectively induces cell death in cancer cells. Initially we treated the different tumor cell lines and non-tumorigenic human cell lines with the LCS101 compound. Exposure of the cultured tumor cells to the compound led to a dose-dependent reduction in cell viability, with cell death observed in >90% of cells, as measured by XTT assay. This phenomenon was observed at concentrations of 1 mg/ml for breast and colon cancer cell lines, and at 3 mg/ml for prostate cancer cell lines. At the same time, the non-tumorigenic human epithelial cell lines MCF10A (breast) and EP#2 (prostate) demonstrated a reduction in viability of <30% following exposure to the botanical compound (Fig. 1A). The non-tumorigenic human luminal breast cell line HB-2 also displayed an attenuated response to LCS101 exposure (not shown). Light microscopy showed increased cell death of all cancer cells following exposure to LCS101 treatment, with some of the treated cancer cells demonstrating swelled morphology indicative of a necrotic process. In contrast, non-tumorigenic human epithelial cells exhibited normal density and morphology following exposure to the compound (Fig. 1B).

LCS101 reduces PARP-1 expression in breast cancer cell lines. To address the mechanisms underlying the anticancer activity of LCS101, MDA-MB-231, MCF7 and MCF10A breast cells were treated with LCS101, and expression of
apoptosis markers caspase-3 (cas-3) and poly(ADP-ribose) polymerase 1 (PARP-1) were examined. In classic apoptosis both of these proteins undergo cleavage, which is considered as hallmark of apoptosis. Surprisingly, no cleavage of caspase-3 and PARP-1 was detected, though a significant reduction in the level of PARP-1 protein was observed in both of these cancer cell lines. In contrast, the non-tumorigenic human epithelial breast MCF10A cells exposed to LCS101 showed no reduction in PARP-1 levels (Fig. 2A).

**LCS101-induced toxicity correlates with reduced PARP-1 levels.** In order to better understand the cytotoxic effects of the LCS101 formulature, 6 of the 14 herbal components were isolated and selected: *Ligustrum lucidum*, *Milletia reticulata*, *Paeonia lactiflora*, *Paeonia obovata*, *Prunella vulgaris* and *Scutellaria barbata*. These herbs were found to display greater toxic effects towards MDA-MB-231 cancer cells, without any harmful effects on the non-tumorigenic human epithelial breast MCF10A cells (not shown). Following these findings, the LCS101 formula was divided into the ‘toxic formula’ (the above-mentioned 6 components) and the ‘non-toxic formula’ (the remaining 8 components). Exposure to the toxic formula resulted in a significant increase in cell death in MCF7 and MDA-MB-231 breast cancer lines, compared to no cytotoxic effect in the non-toxic formula (Fig. 2B and C). Following exposure to the toxic formula, cell swelling was observed in treated MDA-MB-231 cells (Fig. 2C, arrows). Both the toxic and non-toxic formulas had

Figure 2. LCS101-induced toxicity correlates with reduction of PARP-1 protein levels. (A) The effect of LCS101 on PARP-1 and caspase-3 (cas-3) in MCF7, MDA-MB-231 and MCF10A cells. (B) Viability of MCF-7, MDA-MB-231 and MCF-10A cells treated with 3 mg/ml of LCS101 or sub-formulas. XTT viability test was performed at 72 h. Error bars in (A) and (B) represent the standard ± deviation. (C) Light microscopy. Black arrows in the right panel point towards the MDA-MB-231 cells with swelling. (D) MDA-MB-231 cells, treated as in (B), and subjected to protein extraction and immunoblotting.

Figure 3. LCS101-induced PARP-1 reduction is unrelated to mRNA or proteasome degradation. (A) MCF7 and MDA-MB-231 cells were plated 6x10^5 cells into 10-cm plates and treated the next day with 3 mg/ml of LCS101. Protein and RNA were extracted 24 h after the beginning of the treatment. Protein was immunoblotted with PARP-1 antibody for PARP-1 protein level detection (upper panel). RNA was subjected to RT-qPCR (lower panel). Error bars represent the standard ± deviation. In both cases GAPDH served as internal control. (B) Western blotting of MCF7 cells treated with 3 mg/ml of LCS101, 10 µM MG132 or both.
no effect on the non-tumorigenic human epithelial breast MCF10A cells (Fig. 2B and C). Finally, while the toxic formula reduced PARP-1 levels in MDA-MB-231 cells, no such effect was observed with the non-toxic components of the formula (Fig. 2D).

LCS101-induced PARP-1 reduction is unrelated to mRNA or proteasomal degradation. To further address the mechanism of PARP-1 protein reduction, we tested PARP-1 mRNA levels in LCS101-treated cells using RT-PCR. PARP-1 mRNA levels in exposed MCF7 and MDA-MB-231 cells were similar to those found in controls (Fig. 3A). We then examined PARP-1 protein degradation using the proteasome inhibitor MG132 on MDA-MB-231 cells. After 24 h of treatment with MG132, which was necessary for LCS101-induced PARP-1 reduction, massive cell death and complete PARP-1 cleavage, characteristic of apoptosis, were observed. However, the examination of MCF7 cells, which apparently were more resistant to MG132-induced apoptosis, found that the MG132 failed to prevent PARP-1 elimination following exposure to the botanical formula (Fig. 3B).

LCS101-induced cell death exhibits necrosis-like features. LCS101-treated cells were analyzed using FACS in order to distinguish between apoptotic and necrotic features. For this purpose, MCF7, MDA-MB-231 and MCF10A cells were treated with LCS101 for 72 h, with each sample divided into two aliquots for FACS analysis. One aliquot was fixed and stained with PI to assess the sub-G1 population, which contained cells with degraded DNA, characteristic of apoptotic death. The second aliquot was used to evaluate the percentage of cells with ruptured membranes, typical of necrotic death, using free PI influx by live unfixed cells. Ruptured membrane of necrotic cells allows free PI uptake which causes the necrotic population to appear very bright on logarithmic PI scale. Following exposure to LCS101, the pattern of the vast majority of the cancer cell lines MCF7 and MDA-MB-231 moved far to the right upon free PI uptake, indicating that most of the cells possessed a necrosis-like ruptured membrane (Fig. 4). Morphologically, a number of the affected cells exhibited significant swelling, typical of a necrotic process as well (Fig. 1B). At the same time, only 20% of the cells exhibited sub-G1 DNA content, a typical indicator of apoptosis (Fig. 4). LCS101 did not induce cell death in the non-tumorigenic human epithelial breast MCF10A cells (Fig. 4).

LCS101 selectively protects non-tumorigenic cells from doxorubicin and 5-FU. Chemotherapy-induced cell death was observed in all three breast cell lines (MCF-10A, MCF-7 and MDA-MB-231) following exposure to the chemotherapy
agent doxorubicin (Fig. 5A). When introduced at a concentration of 3 mg/ml, LCS101 augmented the tumoricidal effects of the chemotherapy in MCF7 and MDA-MB-231 cells. In contrast, the addition of the botanical formula to the non-tumorigenic human epithelial breast MCF10A cells greatly reduced cell death (Fig. 5A and C). A similar selective effect

Figure 5. LCS101 selectively protects non-tumorigenic cells from chemotherapy-induced death, without interfering with toxicity to cancer cells. Breast cell lines were treated with rising concentrations of doxorubicin (Doxo) or 5-fluorouracil (5-FU), either alone or in combination with 3 mg/ml LCS101. After 72 h of treatment the viability of cells was tested by XTT (A, Doxo; B, 5-FU). Protection of MCF10A cells from doxorubicin-induced death was also examined by light microscopy (C).

Figure 6. LCS101 selectively reduces PARP-1 levels in doxorubicin-treated cancer cells. MDA-MB-231 (A), MCF10 and MCF7 (B) cells were treated with 3 mg/ml of LCS101, 1 µM doxorubicin or both. Protein was extracted 24-72 h after the beginning of the treatment for MDA-MB-231 cells and 72 h after the beginning of the treatment for MCF10A and MCF7 cells, resolved by SDS-PAGE and immunoblotted with PARP-1 antibody and tubulin/β-actin for loading control.
was seen in 5-FU-treated cell lines, with LCS101 increasing the tumoricidal effect of the chemotherapy agent on MCF7 and MDA-MB-231 cells, while reducing cell death in the non-tumorigenic human epithelial breast MCF10A cells (Fig. 5B). In addition to the above findings, MDA-MB-231 cells treated with doxorubicin demonstrated PARP-1 cleavage typical of apoptosis, at 48 and at 72 h (Fig. 6A). A less prominent but still clearly detectable PARP-1 cleavage was observed in MCF10A and MCF7 cells at 72-h treatment with doxorubicin (Fig. 6B). The addition of LCS101 to doxorubicin-treated MDA-MB-231 and MCF7 cells, however, led to the disappearance of PARP-1 cleavage altogether, supporting our previous findings showing protective effect of LCS101 in normal cells.

In order to confirm the above findings, we performed FACS analysis of MDA-MB-231, MCF7 and MCF10A cells, which were treated with both doxorubicin and LCS101 (Fig. 4). Our findings were consistent with those above regarding PARP-1 cleavage, with typical apoptosis observed in all three cell lines treated with doxorubicin alone and a clearly demarked sub-G1 apoptotic population. At the same time, the addition of LCS101 reduced apoptosis in non-tumorigenic human epithelial breast MCF10A cells, while increasing cell death in the two cancer cell lines (Fig. 4). In cancer cells treated with both LCS101 and doxorubicin, cell death exhibited necrotic features, as described above. This indicates that the increase in doxorubicin-induced cell death in cancer cell lines treated with LCS101 results from a necrosis-like process. At the same time, LCS101 offers a protective effect on non-tumorigenic cells exposed to the chemotherapy agent.

Table I. Anticancer effects of LCS101 herbal components.

<table>
<thead>
<tr>
<th>Herbal component</th>
<th>Anticancer effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Astragalus membranaceus</em></td>
<td>Suppression of C6 glioma cells, <em>in vitro</em> and <em>in vivo</em> (9)</td>
</tr>
<tr>
<td><em>Atractylodes macrocephala</em></td>
<td>Mediation of reactive oxygen species apoptosis in human leukemia cells (10)</td>
</tr>
<tr>
<td><em>Citrus reticulate</em></td>
<td>Induction of apoptosis in SNU-C4 human colon cancer cells (11)</td>
</tr>
<tr>
<td></td>
<td>Induction of apoptosis in human gastric cancer cells (cas-3 pathway) (12)</td>
</tr>
<tr>
<td><em>Ligustrum lucidum</em></td>
<td>Induction of human glioma cell death through regulation of Akt/mTOR pathway <em>in vitro</em> and reduction of glioma tumor growth in U87MG xenograph mouse model (13)</td>
</tr>
<tr>
<td><em>Oldenlandia diffusa</em></td>
<td>Augmentation of oxidative burst in macrophages and inhibited tumor growth (14)</td>
</tr>
<tr>
<td></td>
<td>Selective anticancer <em>in vitro</em> effects in B16-F10 mice lung cancer and Renca renal carcinoma models (15)</td>
</tr>
<tr>
<td><em>Paeonia lactiflora</em></td>
<td>Inhibition of bladder cancer growth in a rat model involving phosphorylation of Chk2, <em>in vitro</em> and <em>in vivo</em> (16)</td>
</tr>
<tr>
<td><em>Prunella vulgaris</em></td>
<td>Chemoprevention of non-small cell lung cancer (NSCLC) via promotion of apoptosis and regulation of the cell cycle (17)</td>
</tr>
<tr>
<td></td>
<td>Suppression of PMA-induced tumor cell invasion and metastasis via inhibition of NF-κB-dependent MMP-9 expression (18)</td>
</tr>
<tr>
<td><em>Scutellaria barbata</em></td>
<td>Induction of oxidative stress damage with redistribution of metabolic fluxes in breast cancer cells (19)</td>
</tr>
<tr>
<td></td>
<td>Selective cytotoxic activity on breast cancer cells (20)</td>
</tr>
<tr>
<td></td>
<td>Augmentation of oxidative burst in macrophages and inhibited tumor growth (14)</td>
</tr>
<tr>
<td></td>
<td>Modulation of apoptosis and cell survival in murine and human prostate cancer cells and tumor development in TRAMP mice (21)</td>
</tr>
</tbody>
</table>

Discussion

The treatment of patients with cancer presents a number of challenges to oncologists. Anticancer therapies, whether chemotherapy or personalized and targeted biological agents, are often only partially effective and are invariably accompanied by debilitating adverse effects which can compromise the treatment regimen. Many tumors are aggressive and resistant to conventional treatments, which themselves can impair the body's immunity and increase susceptibility to infection. The use of additional chemotherapy agents to established regimens can further increase tumor response, though this positive effect is offset by increased toxicity (8).

Botanical medicine has been in use for thousands of years, with pre-clinical and clinical research demonstrating a number of positive effects of many of the herbal compounds being used for the treatment of cancer, with reduction of disease activity and treatment-related symptoms. In the present study we found the botanical compound LCS101 demonstrated a dose-dependent induction of cell death in
breast, prostate and colorectal cancer cells. At the same time, LCS101 exhibited no cytotoxic effects on non-tumorigenic human epithelial breast MCF10A cells. The cytotoxic effects of many of the individual LCS101 components have been reported elsewhere in the scientific literature (Table I). Little is known, however, about the selectivity of these effects, and the potential for negative effects on non-tumorigenic cells has limited their use in clinical practice. In light of this, the findings of the present study may have significant implications regarding the incorporation of botanical products into standard anticancer care.

LCS101-induced cancer cell death was manifest as both rupturing of the cell membrane and, in some cases, cell swelling. Both phenomena are demonstrative of a necrotic pathway. The absence of caspase-3 cleavage and lack of DNA degradation despite the massive cell death observed provides further evidence supporting the understanding that this was a manifestation of necrotic cell death. At the same time, however, LCS101-induced cancer cell death was associated with a drastic drop in PARP-1 protein levels, a phenomenon not reported elsewhere in the literature, to the best of our knowledge. This was also observed in the correlation between PARP-1 reduction and cytotoxic effects of the toxic and non-toxic sub-formulas of the botanical compounds. The reduction in PARP-1 levels was not related to either reduction in mRNA expression or proteasomal degradation. Further research is needed in order to understand the implications and mechanisms of these effects on PARP-1 pathways.

We also evaluated the effects of LCS101 on cells treated with the chemotherapy agents doxorubicin and 5-FU. As expected, these agents led to significantly reduced survival in all cell lines. However, while cell death was significantly increased in breast cancer cell lines MCF-7 and MDA-MB-231 following the addition of the botanical compound, non-tumorigenic human epithelial breast MCF-10A cells were protected from doxorubicin-induced apoptosis. These findings further support the results observed in earlier clinical trials, in which LCS101 was found to be safe and non-toxic when administered to patients with cancer.

TCM employs a holistic, personalized approach to the treatment of disease. The use of herbal formulas which combine a number of herbal products, each with its own effects on the body acting in harmony with each another, enhances the therapeutic process and promotes well-being. We believe that for this reason, the toxic components need to be supplemented by the non-toxic components in order to promote healing. Many of the LCS101 components have indeed been shown to have anticancer and immunomodulatory effects, as well as demonstrating protective effects against chemotherapy and reactive oxygen species (Table I).

In conclusion, our findings strongly support our previous data suggesting that LCS101 has a cytotoxic effect on cancer cell lines. Furthermore, we show that LCS101 cytotoxicity is selective, with no deleterious effects on non-tumorigenic epithelial cells. LCS101-induced cancer cell death resembles necrosis, though further research is needed in order to better understand this mechanism. In addition, LCS101 provides a selectively protective effect on non-tumorigenic epithelial cells exposed to the chemotherapy agents doxorubicin and 5-FU, while at the same time augmenting their cytotoxic effects on cancer cell lines. Further research is needed to support these findings, as well as understand the clinical implications of this particular botanical compound on anticancer therapy.

Acknowledgments

Conflict of interest statement: Dr Yair Maimon is a shareholder of LifeBiotics Ltd.

References


